Clinical Effect of Erchentang and Bixie Fenqingyin Combined on Patients with Acute Cerebral Infarction with Hyperuricemia with Syndrome of Phlegm and Blood Stasis Blocking Collaterals

XU Zhaohui; LI Guoyi; ZHAO Qing; CHENG Jiwei

doi:10.13422/j.cnki.syfjx.20232298

您当前的位置：

首页 >

文章列表页 >

Clinical Effect of Erchentang and Bixie Fenqingyin Combined on Patients with Acute Cerebral Infarction with Hyperuricemia with Syndrome of Phlegm and Blood Stasis Blocking Collaterals

更新时间：2023-06-30

- Clinical Effect of Erchentang and Bixie Fenqingyin Combined on Patients with Acute Cerebral Infarction with Hyperuricemia with Syndrome of Phlegm and Blood Stasis Blocking Collaterals
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 15, Pages: 79-87(2023)
- 作者机构：
  
  1.上海中医药大学附属普陀医院，上海 200062
  2.上海中医药大学附属曙光医院，上海 201203
  3.上海市养志康复医院（上海市阳光康复中心）/同济大学附属养志康复医院，上海 201619
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20232298
  CLC： R2-0;R22;R285.5;R2-031;R259;R255.2;R743.3
- Published：05 August 2023，
  
  Published Online：07 June 2023，
  
  Received：15 March 2023，
- 稿件说明：
扫描看全文
徐朝辉,李国毅,赵卿等.二陈汤合萆薢分清饮治疗急性脑梗死伴高尿酸血症痰瘀阻络证患者的临床疗效[J].中国实验方剂学杂志,2023,29(15):79-87.

XU Zhaohui,LI Guoyi,ZHAO Qing,et al.Clinical Effect of Erchentang and Bixie Fenqingyin Combined on Patients with Acute Cerebral Infarction with Hyperuricemia with Syndrome of Phlegm and Blood Stasis Blocking Collaterals[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(15):79-87.
徐朝辉,李国毅,赵卿等.二陈汤合萆薢分清饮治疗急性脑梗死伴高尿酸血症痰瘀阻络证患者的临床疗效[J].中国实验方剂学杂志,2023,29(15):79-87. DOI： 10.13422/j.cnki.syfjx.20232298.

XU Zhaohui,LI Guoyi,ZHAO Qing,et al.Clinical Effect of Erchentang and Bixie Fenqingyin Combined on Patients with Acute Cerebral Infarction with Hyperuricemia with Syndrome of Phlegm and Blood Stasis Blocking Collaterals[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(15):79-87. DOI： 10.13422/j.cnki.syfjx.20232298.

摘要

目的

探讨二陈汤合萆薢分清饮治疗急性脑梗死伴高尿酸血症痰瘀阻络证患者的临床疗效及安全性，拟为急性脑梗死伴高尿酸血症的治疗提供新的方法和依据。

方法

选取上海中医药大学附属普陀医院2021年5月—2022年5月符合标准的急性脑梗死伴高尿酸血症痰瘀阻络证患者132例，随机分为中药组、西药组及对照组（每组各44例）。3组均予以急性脑梗死西医常规疗法，中药组在此基础上服用二陈汤合萆薢分清饮，西药组在此基础上服用苯溴马隆片，对照组则不予以任何降尿酸治疗，治疗疗程为4周。通过观察患者发病3个月后改良Rankin量表（mRS）评分及治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分、中医证候积分、血尿酸（SUA）水平、血清C反应蛋白（CRP）和白细胞介素-6（IL-6）水平、血清超氧化物歧化酶（SOD）和丙二醛（MDA）水平及其他安全性指标。

结果

最终完成试验观察病例129例，中药组43例，西药组42例，对照组44例。中药组预后良好率（83.7%，36/43）优于西药组（64.3%，27/42）及对照组（40.9%，18/44）（

=4.184，16.930，

0.05），西药组优于对照组（

=4.70，

0.05）。治疗后3组患者NIHSS评分、中医证候积分、SUA、CRP、IL-6、MDA水平均较治疗前降低，SOD水平升高（

0.05）。其中，中药组和西药组NIHSS评分改善程度均优于对照组（

0.05）；中药组中医证候改善程度最优（

0.05）；西药组降尿酸程度最优（

0.05）。3组治疗前后各项安全性指标均未出现明显异常，未见严重不良反应。

结论

二陈汤合萆薢分清饮治疗能显著改善急性脑梗死伴高尿酸血症痰瘀阻络证患者的预后、早期神经功能缺损及中医证候，降低血尿酸水平，抑制炎症反应及氧化应激反应。

Abstract

Objective

To explore the clinical efficacy and safety of the combination of Erchentang and Bixie Fenqingyin in the treatment of patients with acute cerebral infarction accompanied by hyperuricemia of phlegm and blood stasis blocking collaterals syndrome to provide a new method and evidence for the treatment of acute cerebral infarction with hyperuricemia.

Method

A total of 132 eligible patients with acute cerebral infarction accompanied by hyperuricemia of phlegm and blood stasis blocking collaterals syndrome admitted to the Putuo Hospital of Shanghai University of Traditional Chinese Medicine（TCM） from May 2021 to May 2022 were randomly divided into a Chinese medicine group， a western medicine group， and a control group， with 44 cases in each group. All three groups received routine western medical treatment for acute cerebral infarction. Additionally， the Chinese medicine group received Erchentang combined with Bixie Fenqingyin， the western medicine group received Benzbromarone tablets， and the control group did not receive any uric acid-lowering treatment. The treatment duration was four weeks. The modified Rankin Scale （mRS） score after three months of onset， as well as the National Institutes of Health Stroke Scale （NIHSS） scores， TCM syndrome scores， serum uric acid （SUA） levels， serum C-reactive protein （CRP） and interleukin-6 （IL-6） levels， serum superoxide dismutase （SOD） and malondialdehyde （MDA） levels， and other safety indicators were observed before and after treatment.

Result

A total of 129 cases completed the trial observation， with 43 cases in the Chinese medicine group， 42 cases in the western medicine group， and 44 cases in the control group. The rate of good prognosis in the Chinese medicine group （83.7%，36/43） was higher than that in the western medicine group （64.3%，27/42） and the control group （40.9%，18/44）（

=4.184，16.930，

0.05）， and the western medicine group was superior to the control group （

=4.707，

0.05）. After treatment， the NIHSS scores， TCM syndrome scores， SUA， CRP， IL-6， and MDA levels of the patients in all three groups decreased， while the SOD levels increased compared with those before treatment （

0.05）. Among them， the improvement in NIHSS score was better in the Chinese medicine group and the western medicine group than in the control group （

0.05）. The Chinese medicine group showed the greatest improvement in TCM syndrome （

0.05）， while the western medicine group showed the greatest reduction in uric acid levels （

0.05）. No significant abnormalities in safety indicators were observed before and after treatment in the three groups， and no serious adverse reactions were reported.

Conclusion

The combination of Erchentang and Bixie Fenqingyin can significantly improve the prognosis， early neurological deficits， and TCM syndromes of patients acute cerebral infarction accompanied by hyperuricemia of phlegm and blood stasis blocking collaterals syndrome. It can also lower uric acid levels and inhibit inflammatory and oxidative stress reactions.

关键词

二陈汤萆薢分清饮急性脑梗死高尿酸血症痰瘀阻络证

Keywords

ErchentangBixie Fenqingyinacute cerebral infarctionhyperuricemiasyndrome of phlegm and blood stasis blocking collaterals

references

GUAN T，MA J，LI M，et al.Rapid transitions in the epidemiology of stroke and its risk factors in China from 2002 to 2013［J］.Neurology，2017，89（1）：53-61.

中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018［J］.中华神经科杂志，2018，51（9）：666-682.

TU W，WU J，JIAN G，et al.Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities［J］.Eur J Clin Nutr，2019，73（10）：1392-1402.

ACAR T，GÜZEY ARAS Y，GÜL S S，et al.Can high uric acid levels be an independent risk factor for acute ischemic stroke due to large-artery atherosclerosis？［J］.Ideggyogy Sz，2018，71（7/8）：279-283.

MOHSIN M，DAS S N，HAQUE M F，et al.Serum uric acid level among acute stroke patients［J］.Mymensingh Med J，2016，25（2）：215-220.、

WEIR C J，MUIR S W，WALTERS M R，et al.Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke［J］.Stroke，2003，34（8）：1951-1956.

本刊讯.国家食品药品监督管理总局提醒警惕别嘌醇片引起重症药疹问题［J］.中国药房，2013，24（45）：4265.

WHITE W B，SAAG K G，BECKER M A，et al.Cardiovascular safety of febuxostat or allopurinol in patients with gout［J］.N Engl J Med，2018，378（13）：1200-1210.

CFDA网站.CFDA：警惕苯溴马隆的肝损害风险［J］.上海医药，2015（5）：39-39.

黄晶，杨婷，王雨，等.痛风病的国内外认识及治疗进展与思考［J］.世界中医药，2021，16（1）：1-7.

徐朝辉，赵卿，白宇.中西医治疗伴高尿酸血症脑梗死的研究进展［J］.中西医结合心脑血管病杂志，2021，19（8）：1310-1314.

王新陆.论脑血辨证［J］.山东中医杂志，2002，21（5）：259-263.

张晋，陈志伟.急性脑梗死合并高血尿酸与中医辨证分型的关系［J］.中医杂志，2006，47（10）：773-774，780.

童建兵，汪瀚，姚实林.脑梗死患者血尿酸水平与中医证候关系研究［J］.中医药临床杂志，2008，20（3）：252-254.

徐朝辉，朱刚，刘传森，等.基于数据挖掘对中医药治疗无症状高尿酸血症的组方用药规律分析［J］.中药药理与临床，2021，37（4）：204-208.

徐朝辉，赵卿，梁彪，等.近11年中医药治疗急性脑梗死的用药规律分析［J］.中西医结合心脑血管病杂志，2022，20（21）：3878-3883.

王美，宋玉强.伴高尿酸血症的急性脑梗死患者血尿酸水平与预后的关系［J］.山东医药，2017，57（28）：94-96.

徐朝辉，黄蓓.急性脑梗死患者中医证型与磁共振弥散加权成像表现的相关性研究水［J］.中国中医急症，2022，31（1）：91-95.

阮永龙，李飞，付恩鸿，等.急性脑梗死OCSP分型及Adams分型与心电图异常的对比研究［J］.安徽医学，2009，30（4）：405-407.

中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识［J］.中华内分泌代谢杂志，2013，29（11）：913-920.

李平，吴钟璇，张云如，等.中风病诊断与疗效评定标准（试行）［J］.北京中医药大学学报，1996，19（1）：55-56.

周仲英.中医内科学［M］.北京：中国中医药出版社，2003，1：324-327.

郑筱萸.中药新药临床研究指导原则［M］.北京：中国医药科技出版社，2002.

国家药品监督管理局.证候类中药新药临床研究技术指导原则［J］.中医药管理杂志，2018，26（21）：107.

张倩，杨凤文，石蒙，等.大黄泄浊方对IgA肾病合并高尿酸血症患者肾小管功能的影响［J］.中国实验方剂学杂志，2023，29（12）：135-141.

徐朝辉，程记伟，石智珍，等.高尿酸血症与急性缺血性卒中患者转归的相关性［J］.国际脑血管病杂志，2021，29（6）：432-436.

王新陆.“浊”与“血浊”［J］.天津中医药，2019，36（9）：833-838.

马冲，陈蕾，宋艳艳，等.从血浊论治缺血性脑卒中［J］.中国中医急症，2018，27（3）：557-558，564.

张明昊，杜婧雯，张童，等.萆薢分清丸通过调控尿酸盐转运蛋白表达水平干预高尿酸血症大鼠的作用机制［J］.中国实验方剂学杂志，2023，29（3）：1-8.

刘艳，孟兆青，张春凤，等.丹参降尿酸作用初步实验研究［J］.海峡药学，2013，25（1）：27-29.

张双金，周燕，魏玉辉，等.茯苓水提物对高尿酸血症大鼠rURAT1rOAT1和rOCT2表达的影响［J］.西部医学，2016，28（12）：1648-1651，1657.

XIA N，LI B，LIU H，et al.Anti-hyperuricemic effect of Plantago depressa Willd extract in rats［J］.Trop J Pharm Res，2017，16（6）：1365.

陈光亮，朱立然，那莎，等.萆薢总皂苷对大鼠慢性高尿酸血症和肾小管尿酸转运体1表达的影响［J］.中国中药杂志，2013，38（14）：2348-2353.

MUIR S W，HARROW C，DAWSON J，et al.Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke：a randomized，double-blind，placebo-controlled trial［J］.Stroke，2008，39（12）：3303-3307.

TAHERAGHDAM A A，SHARIFIPOUR E，PASHAPOUR A，et al.Allopurinol as a preventive contrivance after acute ischemic stroke in patients with a high level of serum uric acid：A randomized，controlled trial［J］.Med Princ Pract，2014，23（2）：134-139.

韩学杰，沈绍功.探讨血管内皮损伤致冠心病心绞痛的发生机理［J］.中国中医基础医学杂志，2001，7（4）：23-24.

裴宇鹏，杨关林，陈智慧，等.构建动脉粥样硬化“痰瘀论治，健脾为要”治则治法新理论体系［J］.中华中医药学刊，2020，38（8）：32-34.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Tongnaoyin on Cerebral Hemodynamics in Patients with Acute Cerebral Infarction of Phlegm and Blood Stasis Syndrome Based on CTA/CTP

Mechanism of Modified Erchentang on COPD Inflammation Based on TNF-α/TNFR1/RIPKs Pathway

Comparison on Rat Models of Acute Cerebral Infarction Due to Stasis Combined with Toxin Complicated with Cerebral-cardiac Syndrome

Modified Erchentang Alleviates Inflammation in Chronic Obstructive Pulmonary Disease via Midkine/Notch2/Hey1 Signaling Pathway in Rats

Shenling Baizhusan Improves Spermatogenesis in Hyperuricemia Oligoasthenospermia Mice by Regulating Nrf2/ARE Pathway

Related Author

JI Lianhong

LIU Peian

LI Li

LI Yunze

ZHU Qing

TANG Xiaogang

JIANG Hui

LIU Yongkang

Related Institution

The Affiliated Hospital of Nanjing University of Chinese Medicine/ Jiangsu Province Hospital of Chinese Medicine

Henan University of Chinese Medicine

Xiyuan Hospital，China Academy of Chinese Medical Sciences

Beijing Key Laboratory of Pharmacology of Chinese Materia Medica，Institute of Basic Medical Sciences，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Henan Provincial Second People's Hospital

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰